A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways

Anti-Cancer Drugs

Volumn 20, Issue 9, 2009, Pages 815-821

  Hwang, Jung Jin ^a   Kim, Yong Sook ^a   Kim, Mi Joung ^a   Jang, Sejin ^a   Lee, Je Hwan ^a   Choi, Jene ^a   Ro, Seonggu ^a   Hyun, Young Lan ^a   Lee, Jung Shin ^a,b   Kim, Choung Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b CrystalGenomics Inc   (South Korea)

Author keywords

Anticancer drug; Apoptosis; Caspase; HCT116; Histone deacetylase inhibitor; K562

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; [2 (ARYLOXYMETHYL) OCT 2 ENEDIOIC ACID 8 HYDROXYAMIDE 1 [(1 AKYL PIPERIDIN 4 YL) AMIDE]]; CASPASE 3; CASPASE 8; CASPASE 9; CG 0006; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; PROTEIN BCL XL; PROTEIN P27; TUBULIN; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN HCT116; CELL STRAIN K 562; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA DETERMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; KIDNEY CANCER; KOREA; LIVER CANCER; LUNG CANCER; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; STOMACH CANCER; WESTERN BLOTTING;

ACETYLATION; BCL-X PROTEIN; CASPASES; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYME INHIBITORS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; PIPERIDINES; TUBULIN;

EID: 70349126890     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283300a0f     Document Type: Article

References (20)

1. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1:194-202.
2. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51.
3. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A 1964; 51:786-794.
4. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003; 4:13-18.
5. Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 2002; 9:322-332.
6. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541-5552.
7. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A 1998; 95:6791-6796.
8. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003; 101:3236-3239.
9. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11:71-76.
10. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004; 23:6261-6271.
11. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63:3637-3645.
12. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280:26729-26734.
13. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003; 100:4389-4394.
14. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006; 5:2767-2776.
15. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001; 98:10833-10838.
16. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006; 281:5612-5622. (Pubitemid 43847658)
17. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 2006; 66:5409-5418.
18. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007; 74:659-671.
19. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006; 5:2086-2095.
20. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005; 25:261-309.